Fractyl Health (GUTS) EBIT (2023 - 2026)

Fractyl Health (GUTS) has reported EBIT for 4 consecutive years, with -$19.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 26.78% year-over-year to -$19.1 million; the trailing twelve-month figure through Jun 2026 stood at -$85.9 million (up 13.97% YoY), and the FY2025 full-year result was -$96.8 million, down 3.51% from the prior year.
• EBIT was -$19.1 million for Q2 2026 at Fractyl Health, up from -$20.8 million in the prior quarter.
• The five-year high for EBIT was -$11.9 million in Q2 2023, with the low at -$26.1 million in Q2 2025.
• Historically, EBIT has averaged -$20.1 million across 4 years, with a median of -$22.1 million in 2024.
• Annual changes were most pronounced in 2024 — EBIT slumped 94.21% — and 2026, when it gained 26.78%.
• Tracing GUTS's EBIT over 4 years: stood at -$13.0 million in 2023, then slumped by 94.21% to -$25.2 million in 2024, then grew by 7.64% to -$23.3 million in 2025, then increased by 17.99% to -$19.1 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$19.1 million in Q2 2026, -$20.8 million in Q1 2026, and -$23.3 million in Q4 2025.